Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease.
The effects of statins in patients with heart failure with preserved ejection fraction (HFpEF) remain unclear. This study aimed to assess whether statin therapy is associated with a decreased risk of mortality in patients with HFpEF. We used data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. The primary outcome was all-cause mortality. We analyzed hazard ratios (HRs) for outcomes with 95% confidence intervals (95% CIs) in patients taking statins compared with those not taking statins using multivariable Cox proportional hazard models. This study included 3378 patients with HFpEF. The mean follow-up period was 3.3years; 497 patients died during the study period. Among all patients, the adjusted HR for all-cause death was significantly lower in those taking statins compared with those not taking statins (HR 0.79, 95% CI 0.63-0.99, P=0.04). The risks of all-cause and cardiovascular mortality in patients without ischemic heart disease (IHD) were significantly lower in those taking statins compared with those not taking statins (HR 0.63, 95% CI 0.44-0.91, P=0.01 and HR 0.59, 95% CI 0.37-0.94, P=0.02, respectively), whereas the risks in patients with IHD did not differ significantly between those taking and not taking statins (HR 0.97, 95% CI 0.72-1.31, P=0.83 and HR 0.95, 95% CI 0.66-1.36, P=0.77, respectively). Among propensity score-matched patients without IHD, the risks of all-cause and cardiovascular death were significantly lower in those taking statins compared with those not taking statins. Statin therapy was associated with improved outcomes in HFpEF patients, particularly those without IHD.